Blinding

Blinding (also called masking) is the practice of concealing the assigned intervention from one or more groups involved in a clinical trial after randomization: participants, the clinicians who treat them, the people who assess outcomes, and sometimes the data analysts. Blinding reduces information bias in how outcomes are reported and measured, and can also reduce differences in extra care, adherence and drop-out between groups. It is distinct from allocation concealment, which keeps upcoming assignments hidden before and during enrollment so that no one can influence who ends up in which group. Labels such as single, double and triple blind are used inconsistently, so trial reports should state exactly who was blinded and how.

Major peptide trials such as STEP 1 (semaglutide), SURMOUNT-1 (tirzepatide) and SELECT were double-blind and placebo-controlled. Blinding can be harder to maintain with GLP-1 receptor agonists, because gastrointestinal effects such as nausea and diarrhea were the most common adverse events with semaglutide in STEP 1. Participants or clinicians who notice such effects may correctly guess the assignment, which is one reason objective outcomes and blinded outcome assessors are valuable in these trials.

Knowing which treatment someone received can change what happens next. A participant who knows they are on the active drug may report feeling better; a clinician may look harder for improvement or give extra care to one group; an assessor may score borderline results differently. Blinding removes these pathways for bias. Schulz and Grimes recommend placing more trust in results when at least the outcome assessments are blinded, except for objective outcomes such as death, which leave little room for bias.

Blinding is often confused with allocation concealment, but they solve different problems. Allocation concealment stops anyone from knowing or predicting the next assignment while participants are being enrolled, which protects the randomization itself. Inadequate concealment has been linked, on average, to exaggerated estimates of treatment effect. Blinding comes afterward and keeps the assignment hidden during treatment and follow-up. A trial can conceal allocation even when blinding is impossible, as in comparisons of surgery with medication.

Blinding can fail when a treatment has noticeable effects. GLP-1 receptor agonists commonly cause nausea and other gastrointestinal symptoms, so participants may correctly guess that they are on the active drug. This does not invalidate the trials, but it means subjective outcomes such as appetite, mood or wellbeing deserve more caution than objective ones such as measured weight or cardiovascular events. Good trial reports describe who was blinded and, where possible, how well blinding held.

“Double blind always means the same thing”

Single, double and triple blind are used differently by different researchers. Double blind may refer to participants and clinicians, or to participants and outcome assessors. Methodologists recommend that trial reports state explicitly which groups were blinded and how, rather than relying on the label alone.

“A double-blind trial is automatically high quality”

Blinding is one safeguard among several. A double-blind trial can still be undermined by poor randomization, inadequate allocation concealment, high drop-out or selective reporting, and a trial that cannot be fully blinded is not automatically inferior. Quality depends on the whole design and how it was carried out.

“Blinding and allocation concealment are the same thing”

Allocation concealment protects the assignment process before a participant is enrolled, preventing selection bias. Blinding hides the assignment afterward, during treatment and outcome assessment. Allocation concealment is possible in virtually every randomized trial, whereas blinding is not always feasible.

What is the difference between single, double and triple blind?

Broadly, single blind usually means participants do not know their assignment, double blind usually adds the investigators or outcome assessors, and triple blind may also include the data analysts or monitoring committee. Because these terms are applied inconsistently, the most reliable approach is to check the trial report for exactly who was kept unaware of assignments.

Why can side effects unblind a trial?

If the active drug causes noticeable effects that placebo rarely does, participants and clinicians may guess who is on which treatment. With GLP-1 receptor agonists, gastrointestinal effects such as nausea are common, so some participants may infer their assignment. This is most likely to bias self-reported outcomes, which is why objective measures and blinded assessors matter.

Can every trial be blinded?

No. Comparisons of surgery with drug treatment, or of very different delivery methods, may be impossible to blind for participants and clinicians. In these cases researchers can still blind outcome assessors and data analysts, use objective outcomes, and always keep allocation concealed during enrollment to protect the randomization.